- $90.49m
- $71.82m
- $0.01m
Genelux Corp expected to post a loss of 20 cents a share - Earnings Preview
Genelux Q1 net loss widens, misses analyst expectations
Brief: Genelux Corporation Announces Pricing Of $20.0 Million Underwritten Public Offering Of Common Stock
Brief: Genelux Corporation Announces Proposed Public Offering of Common Stock
Brief: Genelux Corp Announces Interim Results From Ongoing Lung Cancer Trials
Immuno-oncology firm Genelux's Q3 net loss beats expectations
Genelux Corp reports results for the quarter ended June 30 - Earnings Summary
Genelux Corp expected to post a loss of 22 cents a share - Earnings Preview
Genelux Q2 net loss widens
SEC Filing
Brief: Genelux Corp Appoints Matt Pulisic As CFO
Brief: Genelux Corp Announces First Patient Dosed In Phase 2 Trial Evaluating Systemic Therapy With Olvi-Vec In Non-Small Cell Lung Cancer
Brief: Genelux Corporation Announces Pricing of Approximately $27.5 Million Underwritten Offering of Common Stock and Accompanying Warrants
U.S. RESEARCH ROUNDUP- Ally Financial, GE Vernova, Navient
Brief: Genelux Corp Files For Mixed Shelf Of Upto $300 Million - SEC Filing
U.S. RESEARCH ROUNDUP- Albemarle, Brown-Forman, Jack in the Box
U.S. STOCKS ON THE MOVE-Danaher, Goldman Sachs, Generac Holdings
U.S. STOCKS ON THE MOVE-3M, RPT Realty, CN Energy
Biopharma firm Genelux gains on naming new CFO